Zollinger-Ellison syndrome (MEN1) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (MEN 1) – Complete Medical Guide

Zollinger‑Ellison Syndrome (MEN 1): A Comprehensive Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum, leading to excessive gastric acid secretion. When ZES occurs as part of the hereditary disorder Multiple Endocrine Neoplasia type 1 (MEN 1), patients are at risk for additional endocrine tumors, most commonly in the parathyroid glands and pituitary.

Key facts

  • Incidence of sporadic ZES ≈ 1 – 3 cases per million people per year.1
  • About 20‑30 % of ZES cases arise in the context of MEN 1.2
  • MEN 1 is inherited in an autosomal‑dominant pattern; each child of an affected parent has a 50 % chance of inheriting the mutation.
  • Both men and women are equally affected, typically presenting between ages 30‑60 in MEN 1 carriers.

Symptoms

Because excess acid injures the gastrointestinal (GI) lining, symptoms vary from mild dyspepsia to severe ulcer disease. In MEN 1, symptoms may be compounded by other endocrine tumors.

Gastro‑intestinal manifestations

  • Refractory abdominal pain – often epigastric, worsens after meals.
  • Peptic ulcer disease – multiple, large, or recurrent ulcers in the stomach, duodenum, or jejunum.
  • Diarrhea – caused by acid inactivation of pancreatic enzymes and mucosal damage.
  • Gastro‑esophageal reflux (GERD) – heartburn that does not respond to standard therapy.
  • Gastro‑intestinal bleeding – melena or hematemesis from ulcer erosion.
  • Nausea & vomiting – especially after large meals.

Symptoms from MEN 1‑related tumors

  • Hyperparathyroidism – kidney stones, bone pain, fatigue, depression.
  • Pituitary adenomas – headaches, visual field defects, hormonal excess (e.g., prolactin, growth hormone).
  • Other pancreatic neuroendocrine tumors (NETs) – may secrete insulin, glucagon, or vasoactive intestinal peptide, producing hypoglycemia, rash, or watery diarrhea.

Systemic clues

  • Weight loss despite normal or increased appetite.
  • Fatigue and anemia from chronic bleeding.
  • Osteoporosis or fractures (due to hyperparathyroidism).

Causes and Risk Factors

ZES develops when gastrin‑producing neuroendocrine cells transform into gastrinomas. The underlying cause differs between sporadic and MEN 1‑associated cases.

Genetic cause (MEN 1)

  • Mutations in the MEN1 tumor‑suppressor gene on chromosome 11q13.3 The gene encodes menin, a protein involved in DNA repair and regulation of cell growth.
  • Loss‑of‑function mutations lead to unchecked proliferation of endocrine cells, producing gastrinomas, parathyroid adenomas, and pituitary tumors.

Sporadic gastrinomas

  • Most arise de novo; somatic mutations in MEN1 or CDKN1B have been identified in up to 40 % of sporadic cases.4
  • Environmental factors appear minimal, but chronic gastritis and Helicobacter pylori infection can exacerbate ulcer disease.

Risk factors for MEN 1‑associated ZES

  • Family history of MEN 1 (first‑degree relative with a confirmed pathogenic variant).
  • Previous diagnosis of hyperparathyroidism or pituitary adenoma.
  • Carriers of a pathogenic MEN1 mutation (identified through genetic testing).

Diagnosis

Diagnosing ZES in the setting of MEN 1 requires a combination of biochemical testing, imaging, and genetic evaluation.

Biochemical tests

  • Fasting serum gastrin – Levels > 1000 pg/mL (or > 10× upper limit) are highly suggestive, especially when gastric pH < 2.
  • Secretin stimulation test – Administration of secretin paradoxically raises gastrin in ZES; an increase ≥ 120 pg/mL after 2 minutes is diagnostic.5
  • Check for parathyroid hormone (PTH) and calcium to screen for hyperparathyroidism, and pituitary hormone panel if symptoms suggest pituitary disease.

Imaging studies

  • Somatostatin receptor scintigraphy (OctreoScan) or 68Ga‑DOTATATE PET/CT – highly sensitive for detecting gastrinomas and other NETs.
  • CT or MRI of the abdomen – identifies tumor size, location, and liver metastases.
  • EUS (Endoscopic Ultrasound) – excellent for small (< 1 cm) pancreatic lesions.

Genetic testing

All patients with ZES should be offered testing for MEN1 mutations. A positive result confirms MEN 1 and triggers screening of family members.

Diagnostic criteria for ZES (MEN 1 context)

  1. Fasting gastrin > 1000 pg/mL (or > 10× ULN) with gastric pH < 2, or a positive secretin stimulation test.
  2. Imaging that localizes a gastrinoma (pancreas or duodenum).
  3. Presence of a pathogenic MEN1 mutation or clinical evidence of other MEN 1 tumors.

Treatment Options

Treatment aims to control acid hypersecretion, remove or control gastrinomas, and manage other MEN 1 tumors.

Acid‑suppression therapy (first line)

  • High‑dose Proton Pump Inhibitors (PPIs) – omeprazole 60‑120 mg/day or equivalent; they are the most effective way to keep gastric pH > 4 and heal ulcers.6
  • PPIs are usually required for life; dose may be titrated based on symptom control and gastrin levels.
  • H2‑blockers are less effective and generally used only as adjuncts.

Surgical management

  • Localized gastrinomas – enucleation or partial pancreaticoduodenectomy (e.g., Whipple) when feasible.
  • Multiple or metastatic disease – debulking surgery to reduce tumor burden and improve symptom control; however, cure rates are low.
  • In MEN 1, gastrinomas are often multiple and small; surgery is considered when tumors are > 2 cm, symptomatic, or growing rapidly.

Medical therapies for unresectable or metastatic gastrinomas

  • Somatostatin analogs (octreotide, lanreotide) – inhibit gastrin release and can shrink tumors.
  • Targeted therapy – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for pancreatic NETs and may stabilize disease.
  • Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors.

Management of other MEN 1 tumors

  • Primary hyperparathyroidism – parathyroidectomy is the definitive therapy; improves calcium balance and bone health.
  • Pituitary adenomas – transsphenoidal surgery, dopamine agonists, or somatostatin analogs depending on hormone secreted.

Lifestyle & supportive measures

  • Small, frequent meals; avoid foods that trigger reflux (caffeine, alcohol, spicy foods).
  • Calcium and vitamin D supplementation if hyperparathyroidism leads to bone loss.
  • Vaccinations for hepatitis B and C if liver metastases require systemic therapy.

Living with Zollinger‑Ellison Syndrome (MEN 1)

Long‑term management requires a multidisciplinary approach.

Regular monitoring

  • Gastrin levels every 6–12 months to gauge disease activity.
  • Annual endoscopy for ulcer surveillance, or sooner if symptoms return.
  • Imaging (CT/MRI or functional PET) every 1–2 years to detect new or growing tumors.
  • Bone densitometry every 2–3 years if hyperparathyroidism is present.

Medication adherence

Take PPIs exactly as prescribed; missing doses can precipitate severe ulcer pain and bleeding.

Genetic counseling

All MEN 1 patients should consult a genetic counselor to discuss testing of relatives and family planning options (pre‑implantation genetic diagnosis, prenatal testing).

Psychosocial support

Living with a chronic, hereditary condition can be stressful. Support groups, mental‑health counseling, and patient‑education resources (e.g., MEN‑1 Foundation) are valuable.

Practical daily tips

  • Keep a symptom diary (pain, meals, medication timing) to discuss with your gastroenterologist.
  • Stay hydrated; chronic diarrhea can lead to electrolyte losses.
  • Maintain a balanced diet rich in protein and low in simple sugars to reduce gastric emptying spikes.
  • Carry an emergency card indicating “Zollinger‑Ellison syndrome, on high‑dose PPIs, possible gastrinoma” for medical personnel.

Prevention

Because MEN 1 is genetic, primary prevention is not possible, but several strategies can reduce disease burden:

  • Early genetic testing of at‑risk relatives allows monitoring before symptoms develop.
  • Prophylactic parathyroid surgery in carriers with rising calcium/PTH can prevent bone loss.
  • Prompt treatment of Helicobacter pylori infection reduces additive ulcer risk.
  • Smoking cessation and limiting NSAID use lower the chance of ulcer complications.

Complications

If left untreated or poorly controlled, ZES (especially with MEN 1) can lead to serious health issues:

  • Recurrent, perforated peptic ulcers – may cause peritonitis and require emergency surgery.
  • Upper GI bleeding – leading to anemia, transfusion dependence, or shock.
  • Gastro‑intestinal obstruction from ulcer scarring or tumor mass effect.
  • Malabsorption – chronic acid inactivates pancreatic enzymes, causing nutrient deficiencies (e.g., vitamin B12, iron).
  • Metastatic gastrinoma – liver is the most common site; can cause hepatic dysfunction.
  • Bone disease – secondary to hyperparathyroidism (osteoporosis, fractures).
  • Pituitary or pancreatic NET sequelae – hormonal excess syndromes (Cushing, acromegaly, hypoglycemia).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with your usual medication.
  • Vomiting blood (bright red) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • High fever (> 38.5 °C / 101 °F) together with abdominal pain – possible perforation or infection.
  • Sudden onset of dizziness, fainting, or rapid heartbeat accompanied by weakness – may signal major blood loss.
  • Severe, persistent diarrhea leading to dehydration (dry mouth, scant urine, dizziness).

Prompt medical attention can be life‑saving and prevent permanent damage.

References:
1. Mayo Clinic. “Zollinger-Ellison syndrome.” Accessed April 2024.
2. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “MEN 1 Overview.” 2023.
3. Goudet C, et al. *The MEN1 Gene and Clinical Management.* Endocr Rev. 2022.
4. Liu J, et al. *Somatic MEN1 Mutations in Sporadic Gastrinomas.* J Clin Endocrinol Metab. 2021.
5. Jensen RT, et al. *Secretin Stimulation Test for Zollinger‑Ellison Syndrome.* Gastroenterology. 2020.
6. NCCN Guidelines Version 3.2024 – Neuroendocrine and Adrenal Tumors.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References